X Genomics announced the Human Variant Genome Project, positioning the Singapore-based startup to serve as a central hub for genetic research data stored on blockchain technology. The platform allows
X Genomics announced the Human Variant Genome Project, positioning the Singapore-based startup to serve as a central hub for genetic research data stored on blockchain technology.
The platform allows scientists, research institutions, and individuals to upload complete genome sequences while maintaining ownership of their information. When researchers or medical institutions access the uploaded data, those who contributed their genetic material receive compensation in GSX tokens, a newly created digital currency tied to the platform. The blockchain architecture encrypts sensitive information, preventing unauthorized access while maintaining transparency for approved users.
Genome sequencing has transformed biomedical research. Comparing genetic sequences across populations reveals how humans differ from one another and illuminates disease mechanisms. Understanding genetic variation unlocks better disease treatments, from cancer to viral infections to genetic mutations. Most people share 99.9 percent of their DNA. X Genomics focuses on the 0.1 percent that varies between individuals, the markers that distinguish health from disease susceptibility.
"Our mission is to create a global human genome data hub, mine the huge genetic data base and maximize the value of genetic data," said Shine Lam, the company's chief executive. "By enabling decentralized genome data storage, X Genomics will enable human genome data to be publicly accessible and ready for sharing while protecting the security and privacy of the data owner."
The startup addresses fundamental cost and coordination problems plaguing genomic research today. Genetic sequencing remains expensive, restricting which populations get studied. Data silos across institutions prevent researchers from accessing larger sample populations needed to draw reliable conclusions. X Genomics integrates data from multiple sources onto a single blockchain network, lowering barriers for researchers while protecting individuals' privacy through encryption and permissioned access.
X Genomics aims to reduce costs across the gene technology industry, improve operational efficiency, and solve coordination problems that hamper research collaboration. The platform coordinates work among genome specialists, research institutions, and scientists across multiple organizations.
The company plans to partner with gene technology firms and scientific research institutions. These collaborations will fuel genetic data analysis and mining on the platform, extracting new insights from larger datasets than any single institution could assemble. X Genomics will use these insights to develop customized health management guidance for individuals based on their genetic profiles.
The project has assembled researchers and geneticists from Singapore, Canada and China. The advisory board includes two Nobel Prize winners: Randy Schekman, who won the 2013 Nobel Prize in Physiology or Medicine, and Eric Maskin, a Harvard professor awarded the 2007 Nobel Prize in Economics. This marks the first blockchain genetics initiative to secure backing from Nobel laureates.
X Genomics will run on the Ethereum blockchain through its ERC-20 token, GSX. Users uploading genome sequences earn tokens when their genetic data enters research projects or gets accessed by approved researchers. Researchers can monetize their work by publishing analyses on the platform for medical institutions or individuals willing to purchase access to their findings. The token serves as currency within the ecosystem and enables liquidity for buyers and sellers of data and research.
The Human Genomic Research Foundation LTD, established in Singapore, manages token issuance and platform governance. The foundation controls how tokens get distributed and sets rules for data access and compensation.
